🔗 Share this article

As America undertakes unprecedented adjustments to its vaccination recommendations, one figure has surfaced unexpectedly: Høeg, a US-based sports physician and public health researcher who rose to prominence by questioning COVID-19 vaccines throughout the pandemic and has zeroed in on alleged fatalities following COVID-19 immunization in her brief tenure at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Schedule

Agency leaders were set to unveil radical revisions to the pediatric immunization program recently, synchronizing the US with the Danish immunization schedule, according to reports – a significant shift that would put the US out of alignment with many the world with little proof for public health gain. This reveal has been pushed back until the coming year.

Instead of the top vaccines chief, Tracy Beth Høeg is set to speak at the meeting. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to head the office this year.

A New Direction at the FDA

The acting appointment may indicate a tighter collaboration between the pharmaceutical and biologics branches as Høeg and Prasad consolidate power at the agency – and it points to a greater focus upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for halting certain pediatric shot schedules in the US so as to align more like Denmark's approach, a society with comprehensive healthcare and a citizenry about the population of Wisconsin’s.

To date statements, she has continued to focus on vaccines – typically the purview of Prasad, head of the FDA’s CBER – instead of medication approval.

Questions Over Expertise

The appointee has little discernible track record in pharmaceutical research, approval processes or management, which has been typical for previous leaders of the biologics center. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a major agency. She has no expertise in pharmaceutical oversight.”

Previous commissioners of the center would “be deeply familiar with laws and regulations and the science of medication creation”, commented Dr. Janet Woodcock. “Objectively, she lacks the sort of resume that prior appointees who headed CBER have had.”

CDER has an enormous workload at the agency, Woodcock stated.

“The public just zeroes in on the innovative therapies, but the off-patent medication office authorizes a multitude of generic medications. There is also a biosimilars program, over-the-counter program and other areas, and all of those must be supervised,” Woodcock explained. “The responsibility you neglect, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a substantial management component to the role, which manages in excess of 5,000 personnel. “It’s a huge leadership role, if you execute it properly,” she added.

Agency Reaction and Contentious Policies

Regarding questions about Dr. Høeg's credentials and whether this selection indicates greater collaboration among regulatory chiefs on vaccines, a representative responded that the “concerns rely on incorrect presumptions”.

“Her resume aligns with the duties of her position,” the spokesperson explained, noting the period Høeg spent advising the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a contentious one-day therapy clearance system that reportedly worried her former heads. “By what process are these therapies being picked for this fast-track system? Who makes the calls?” Dr. Howard asked. “There is a lot of secrecy occurring at the regulatory body right now.”

Broadly speaking, he said, “the Food and Drug Administration seems to be moving towards less stringent oversight of most medications, aside from shots.”

Documented Track Record on Immunizations

Regarding immunizations, Dr. Høeg has a clearer, if troubling, past, critics have noted. She authored a study using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after Covid vaccination. She consulted for the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed altering rules for recently developed shots and discontinuing “optional” immunizations, she stated following the vote on a online show. At the FDA, Høeg has allegedly proposed preventing teenage boys from receiving Covid vaccinations.

“She’s an all-around dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the data in a highly deceptive, fraudulent manner,” Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other dissenters, {like|